Articles by Dr.
Latest articles from the Micro-Gallery column
Micro-Gallery
Beyond the Microscope: Best Practices for Reproducible and Accessible Scientific Imaging in Biotech
Micro-Gallery
How Biotech Microscopy Images Drive Research: Meiji Techno’s Role in Cell, Gene, and Agricultural Innovations
Micro-Gallery
One-Step Nanoscale Expansion Microscopy: Seeing Single Protein Shapes at 1 nm Resolution
Micro-Gallery
Exploring Biotech Microscopy Images: How Meiji Techno Microscopes Power Modern Biotechnology
Micro-Gallery
Revolutionizing Nanoscale Imaging: How Multicolor Electron Microscopy Unlocks Cellular Secrets with Standard Dyes
Micro-Gallery
Beyond the Lens: How ZEISS Microscopy is Rewriting the Economics of Biotech Drug Discovery
Micro-Gallery
From Ancient Microalgae to Nanoscale Imaging: The Hidden Infrastructure of Biotech Microscopy
Micro-Gallery
AI-Enhanced Wave Optics: A New Frontier in High-Fidelity Intravital Imaging and Its Implications for Biotech
Micro-Gallery
Beyond the Lens: How the University of Georgia’s Biomedical Microscopy Core Powers Biotech Innovation
Micro-Gallery
Unlocking the Microverse: How the NIH’s Free Microscopy Image Gallery Powers Noncommercial Biotech Education
Micro-Gallery
The Hidden Signal in Neurocrine’s Discount Acquisition of Soleno: Europe’s Shifting Rare Disease Calculus
Micro-Gallery
Odyssey Therapeutics Second IPO Attempt: A Signal of Biotech Market Thaw or Strategic Pivot?
Micro-Gallery
When Data Turns Political: Understanding the Hidden Boundaries of Content Moderation in AI-Driven Systems
Micro-Gallery
Beyond the Prize: How Three Gene Therapy Pioneers Unlocked a Multi-Billion Dollar Medical Revolution
Micro-Gallery
Muscle Loss Economy: How Tirzepatide vs Semaglutide Differential Effects Reshape Obesity Drug Long-Term Value
Micro-Gallery
Kailera's $625M IPO: Record-Breaking Biotech Exit Signals a Shift in Early-Stage Financing
Micro-Gallery
Revolution Medicines Buyout Price Surge: The Hidden Signal in Pancreatic Cancer Drug RMC-4630
Micro-Gallery
Biovac’s $108 Million Vaccine Factory: A Strategic Pivot in Africa’s Pharmaceutical Supply Chain
Micro-Gallery
Kailera IPO Interview: CEO Renaud on Biotech Market Realities, China Strategy, and the Obesity Pipeline
Micro-Gallery
Beyond the Next Phase: Roche’s Elevidys Trial Signals a Strategic Shift in Duchenne Gene Therapy
Micro-Gallery
FDA Peptide Reclassification: A Strategic Shift for Telehealth and Compounding Pharmacies
Micro-Gallery
Beyond Shelving: How Bristol Myers Squibb's Beeline Deal Reveals a New Pharma Asset Strategy
Micro-Gallery
Beyond the $108M: How Terremoto's Covalent Drug Bet Reflects a Shift in Biotech Investment Strategy
Micro-Gallery
China's Biopharma Dominance in 2026: Decoding the $55 Billion M&A Surge and Strategic Licensing Shift
Micro-Gallery
Beyond the Headline: How Revolution Medicines' $2B Raise and XBI's Surge Signal a Biotech Paradigm Shift
Micro-Gallery
The Invisible Pressure: How External Influence Threatens the Scientific Core of FDA Drug Reviews
Micro-Gallery
Beyond the Headlines: Decoding the Strategic Calculus Behind Biogen-Apellis and Telix's Mega-Financing
Micro-Gallery
Beyond the 11.3% Surge: Decoding the Post-Election Biotech Rally and Its Market Implications
Micro-Gallery
Beyond the FDA Delay: How Eli Lilly's Foundayo Request Signals a New Era in Biopharma Risk Assessment
Micro-Gallery
Beyond Proteinuria: How Filspari's FSGS Approval Signals a New Era in Nephrology Treatment Paradigms
Micro-Gallery
Beyond Sotorasib: How Next-Gen KRAS Drugs Are Redefining the $25 Billion Lung Cancer Market
Micro-Gallery
Beyond the $300M Deal: How Eli Lilly's CrossBridge Bio Acquisition Reveals a New Oncology Strategy
Micro-Gallery
Beyond the Patent Cliff: How Johnson & Johnson's Dual-Engine Strategy Aims to Outrun Stelara's LOE
Micro-Gallery
Beyond the Headline: Decoding the Strategic Silence in Endpoints' Q2 2026 Biopharma Sentiment Survey
Micro-Gallery
Beyond the $1.5 Billion Headline: Decoding the Strategic Logic Behind Biotech's Latest Stock Offering Wave
Micro-Gallery
Beyond the CRL: How Replimune's Double FDA Rejection Signals Deeper CMC Crisis in Oncolytic Virus Development
Micro-Gallery
Beyond the Search: Why the FDA's Year-Long Hunt for a Biologics Director Signals Deeper Regulatory Shifts
Micro-Gallery
Beyond Price Controls: How U.S. Policy Shifts Threaten the Innovation Engine of Small Biotech
Micro-Gallery
Beyond the Headline: How RMC-6236's Success Redefines the Economics of KRAS-Targeted Cancer Therapy
Micro-Gallery
BioNTech's HER2 ADC Breakthrough: How a Licensed Asset Could Reshape the Breast Cancer Market and ADC Strategy
Micro-Gallery
Beyond the $470M Deal: How Regeneron's Telix Move Signals a Radiopharmaceutical Land Grab
Micro-Gallery
Beyond the Headlines: How Neomorph's $100M and Spyre's Trial Data Signal a Shift in Biotech Investment Strategy
Micro-Gallery
Beyond the Headlines: Decoding the Surge in Biotech IPOs for Seaport, Hemab, and Kailera
Micro-Gallery
Beyond the Rejection: How the FDA's RP1 Decision Reveals a Critical Shift in Cancer Therapy Standards
Micro-Gallery
Ailux's 2027 Clinical Trial Target: Decoding the AI Biotech Hiring Strategy Behind China's Pharma Ambition
Micro-Gallery
Roche's $2B+ DAC Bet: Decoding the Neurology-Focused C4 Therapeutics Deal & Its Strategic Implications
Micro-Gallery
Beyond the Headlines: How Shionogi's BARDA Deal and Scinai's CDMO Signal a Strategic Pivot in Pandemic Preparedness
Micro-Gallery
Beyond the Hype: How Mental Health Chatbots Are Proving Their Worth in a Crowded Market
Micro-Gallery
Beyond the Deal Flow: How FTC Court Losses and $500B in Firepower Are Reshaping Biopharma M&A in 2024
Micro-Gallery
AbbVie's 340B 'Patient' Redefinition: A Strategic Move to Reshape Drug Discount Economics
Micro-Gallery
GSK's Five-Phase 3 Gamble: Decoding the Strategy Behind a Chinese-Licensed Gynecological Cancer ADC
Micro-Gallery
Beyond the IPO: How Avalyn Pharma's Inhaled Therapies Could Reshape the $4 Billion Pulmonary Fibrosis Market
Micro-Gallery
Beyond the $137M: How Sidewinder's DAR 4 Bispecific ADC Platform Redefines Oncology Investment
Micro-Gallery
Beyond Rejuvenation: How Life Biosciences' $80M Gene Therapy Funding Signals a New Investment Paradigm in Biotech
Micro-Gallery
Beyond the $400M Deal: How UHS's Talkspace Acquisition Redefines Behavioral Health Integration
Micro-Gallery
Gilead's $4.3 Billion Bet: Decoding the Strategic Pivot from HIV Dominance to Liver & Oncology Leadership
Micro-Gallery
Insmed's Brinsupri Failure: A Case Study in Pipeline Repurposing Risks and Biotech Strategy
A visual journey into the microscopic world, featuring stunning images of cellular structures, protein complexes, and biological processes captured by scientists this month.